Chemotherapy and Tamoxifen for Breast Cancer

Richard J. Santen, Johannes D. Veldhuis, Harold Harvey, Allan Lipton, C. A. Hubay, O. H. Pearson, Bernard Fisher, Carol Redmond, Ann Brown, Norman Wolmark

Research output: Contribution to journalLetter

4 Citations (Scopus)

Abstract

To the Editor: Fisher et al. compared the use of melphalan (lphenylalanine mustard) plus fluorouracil with the use of the antiestrogen tamoxifen plus melphalan and fluorouracil in a large trial of adjuvant therapy in 1863 women with primary breast carcinoma and positive axillary nodes.1 Older women benefited from the addition of tamoxifen, whereas those below 49 years old had no substantial prolongation of disease-free survival. This finding raises two important biologic questions: How effective an antiestrogen is tamoxifen at the dose used (10 mg twice a day) in premenopausal patients? Does melphalan plus fluorouracil cause a”chemical oophorectomy” in premenopausal.

Original languageEnglish (US)
Pages (from-to)1014-1015
Number of pages2
JournalNew England Journal of Medicine
Volume305
Issue number17
DOIs
StatePublished - Oct 22 1981

Fingerprint

Melphalan
Tamoxifen
Fluorouracil
Estrogen Receptor Modulators
Breast Neoplasms
Drug Therapy
Mustard Plant
Ovariectomy
Disease-Free Survival
Therapeutics

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Santen, R. J., Veldhuis, J. D., Harvey, H., Lipton, A., Hubay, C. A., Pearson, O. H., ... Wolmark, N. (1981). Chemotherapy and Tamoxifen for Breast Cancer. New England Journal of Medicine, 305(17), 1014-1015. https://doi.org/10.1056/NEJM198110223051713
Santen, Richard J. ; Veldhuis, Johannes D. ; Harvey, Harold ; Lipton, Allan ; Hubay, C. A. ; Pearson, O. H. ; Fisher, Bernard ; Redmond, Carol ; Brown, Ann ; Wolmark, Norman. / Chemotherapy and Tamoxifen for Breast Cancer. In: New England Journal of Medicine. 1981 ; Vol. 305, No. 17. pp. 1014-1015.
@article{6d45d29ae60a4ab8aaa6b8a25b4813af,
title = "Chemotherapy and Tamoxifen for Breast Cancer",
abstract = "To the Editor: Fisher et al. compared the use of melphalan (lphenylalanine mustard) plus fluorouracil with the use of the antiestrogen tamoxifen plus melphalan and fluorouracil in a large trial of adjuvant therapy in 1863 women with primary breast carcinoma and positive axillary nodes.1 Older women benefited from the addition of tamoxifen, whereas those below 49 years old had no substantial prolongation of disease-free survival. This finding raises two important biologic questions: How effective an antiestrogen is tamoxifen at the dose used (10 mg twice a day) in premenopausal patients? Does melphalan plus fluorouracil cause a”chemical oophorectomy” in premenopausal.",
author = "Santen, {Richard J.} and Veldhuis, {Johannes D.} and Harold Harvey and Allan Lipton and Hubay, {C. A.} and Pearson, {O. H.} and Bernard Fisher and Carol Redmond and Ann Brown and Norman Wolmark",
year = "1981",
month = "10",
day = "22",
doi = "10.1056/NEJM198110223051713",
language = "English (US)",
volume = "305",
pages = "1014--1015",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "17",

}

Santen, RJ, Veldhuis, JD, Harvey, H, Lipton, A, Hubay, CA, Pearson, OH, Fisher, B, Redmond, C, Brown, A & Wolmark, N 1981, 'Chemotherapy and Tamoxifen for Breast Cancer', New England Journal of Medicine, vol. 305, no. 17, pp. 1014-1015. https://doi.org/10.1056/NEJM198110223051713

Chemotherapy and Tamoxifen for Breast Cancer. / Santen, Richard J.; Veldhuis, Johannes D.; Harvey, Harold; Lipton, Allan; Hubay, C. A.; Pearson, O. H.; Fisher, Bernard; Redmond, Carol; Brown, Ann; Wolmark, Norman.

In: New England Journal of Medicine, Vol. 305, No. 17, 22.10.1981, p. 1014-1015.

Research output: Contribution to journalLetter

TY - JOUR

T1 - Chemotherapy and Tamoxifen for Breast Cancer

AU - Santen, Richard J.

AU - Veldhuis, Johannes D.

AU - Harvey, Harold

AU - Lipton, Allan

AU - Hubay, C. A.

AU - Pearson, O. H.

AU - Fisher, Bernard

AU - Redmond, Carol

AU - Brown, Ann

AU - Wolmark, Norman

PY - 1981/10/22

Y1 - 1981/10/22

N2 - To the Editor: Fisher et al. compared the use of melphalan (lphenylalanine mustard) plus fluorouracil with the use of the antiestrogen tamoxifen plus melphalan and fluorouracil in a large trial of adjuvant therapy in 1863 women with primary breast carcinoma and positive axillary nodes.1 Older women benefited from the addition of tamoxifen, whereas those below 49 years old had no substantial prolongation of disease-free survival. This finding raises two important biologic questions: How effective an antiestrogen is tamoxifen at the dose used (10 mg twice a day) in premenopausal patients? Does melphalan plus fluorouracil cause a”chemical oophorectomy” in premenopausal.

AB - To the Editor: Fisher et al. compared the use of melphalan (lphenylalanine mustard) plus fluorouracil with the use of the antiestrogen tamoxifen plus melphalan and fluorouracil in a large trial of adjuvant therapy in 1863 women with primary breast carcinoma and positive axillary nodes.1 Older women benefited from the addition of tamoxifen, whereas those below 49 years old had no substantial prolongation of disease-free survival. This finding raises two important biologic questions: How effective an antiestrogen is tamoxifen at the dose used (10 mg twice a day) in premenopausal patients? Does melphalan plus fluorouracil cause a”chemical oophorectomy” in premenopausal.

UR - http://www.scopus.com/inward/record.url?scp=0019780634&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019780634&partnerID=8YFLogxK

U2 - 10.1056/NEJM198110223051713

DO - 10.1056/NEJM198110223051713

M3 - Letter

VL - 305

SP - 1014

EP - 1015

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 17

ER -